Preoperative CA 125 is significant indicator of curative resection in gastric cancer patients

Table 1 Causes for a non-curative operations

	Peritoneal dissemination	Direct invasion	Distant metastasis	Incomplete resection	Total
Peritoneal dissemination	15	3	3		21
Direct invasion	3	13			16
Distant metastasis	3		3		6
Incomplete resection				6	6
Total	21	16	6	6	49

Table 2 Univariate and multivariate analysis of the risk factors for a non-curative operations n (%)

Variables	Univariate analysis			Multivariate analysis
	Curative	Non-curative	P value	HR (95%CI)	P value
Age, yr			0.189		0.238
< 60	272 (95.1)	14 (4.9)
≥ 60	364 (92.6)	29 (7.4)		1.599 (0.733-3.487)
Sex			0.574		0.642
Male	417 (93.3)	30 (6.7)
Female	219 (94.4)	13 (5.6)		0.832 (0.384-1.803)
Differentiation			0.080		0.082
Differentiated	382 (95.0)	20 (5.0)
Undifferentiated	254 (91.7)	23 (8.3)		1.937 (0.919-4.085)
Location			< 0.001		< 0.001
Lower 1/3	359 (93.2)	26 (6.8)
Middle 1/3	212 (97.2)	6 (2.8)		0.334 (0.120-0.928)	0.036
Upper 1/3	60 (90.9)	6 (9.1)		1.223 (0.421-3.555)	0.711
Whole	5 (50.0)	5 (50.0)		21.303 (4.985-91.036)	< 0.001
CEA			0.038
Negative	579 (94.3)	35 (5.7)			0.792
Positive	57 (87.7)	8 (12.3)		1.142 (0.427-3.056)
CA 19-9			< 0.001		< 0.001
Negative	586 (95.6)	27 (4.4)
Positive	50 (75.8)	16 (24.2)		5.883 (2.569-13.474)
CA 125			< 0.001		< 0.001
Negative	616 (95.7)	28 (4.3)
Positive	20 (57.1)	15 (42.9)		15.549 (6.473-37.352)

CEA: Carcinoembryonic antigen; CA: Carbohydrate antigen.

Table 3 Univariateand multivariate analysis of prognostic risk factors for disease-free survival after curative operations

Variables	Univariate analysis		Multivariate analysis
	5-year DFS	P value	HR (95%CI)	P value
Age, yr		0.865		0.282
< 60 (n =272)	78.3%
≥ 60 (n = 364)	80.1%		1.250 (0.833-1.877)
Sex		0.194		0.037
Male (n = 417)	78.3%
Female (n = 219)	81.7%		0.616 (0.391-0.971)
Differentiation		0.020		0.292
Differentiated (n = 382)	81.6%
Undifferentiated (n = 254)	75.6%		0.797 ( 0.524-1.215)
Location		0.004		0.454
Lower 1/3 (n = 359)	76.0%
Middle 1/3 (n = 212)	86.8%		0.797 (0.489-1.297)
Upper 1/3 (n = 60)	70.8%		1.172 (0.643-2.135)
Whole (n = 5)	40.0%		0.487 (0.138-1.720)
Lymphovascular invasion		< 0.001		0.709
Negative (n = 513)	81.8%
Positive (n = 123)	69.4%		1.085 (0.708-1.662)
Perineural invasion		< 0.001		0.072
Negative (n = 582)	81.4%
Positive (n = 54)	54.4%		1.629 (0.958-2.770)
Stage		< 0.001		< 0.001
IA (n = 292)	98.7%
IB (n = 102)	89.4%		6.613 (1.703-25.674)	0.006
II (n = 75)	79.8%		15.415 (4.297-55.300)	< 0.001
IIIA (n = 69)	49.5%		43.857 (12.999-147.966)	< 0.001
IIIB (n = 39)	46.2%		66.090 (18.643-234.289)	< 0.001
IV (n = 59)	32.7%		93.720 (27.252-319.103)	< 0.001
CEA		< 0.001		0.073
Negative (n = 579)	82.1%		1.559 (0.959-2.535)
Positive (n = 57)	51.3%
CA 19-9		< 0.001		0.694
Negative (n = 586)	81.7%
Positive (n = 50)	51.7%		0.901 (0.535-1.516)
CA 125		< 0.001		0.020
Negative (n = 616)	80.6%
Positive (n = 20)	30.8%		2.431 (1.153-5.123)